Abstract:OPIOIDS are among the most widely used drugs in medicine and are used for the management of acute and chronic pain from a wide variety of disorders. A report in the current issue of ANESTHESIOLOGY by Aubrun et al. affords an opportunity to reconsider and reexamine the role of opioids in pain management and also to review the realistic expectations for pain relief and relief of other symptoms for patients receiving opioids for acute pain. It is worthwhile to begin by defending the uses of these drugs. Opioids are important components of many general anesthetic regimens. They have essential roles in the management of acute pain. For the majority of patients with cancer and sickle cell disease, and for patients in palliative care, opioids are effective in providing pain relief with a tolerable side-effect profile, particularly if mild-to-moderate degrees of sedation are considered acceptable. The risk of addiction in hospitalized patients who receive opioids for pain is quite low. Contrary to common belief, opioids also provide analgesia for some patients with neuropathic pain and even for a subgroup of patients with phantom limb pain after amputation. Aubrun et al. examined morphine administration and pain relief in more than 3000 postoperative patients in the PACU, using a standardized titration procedure. Specifically, pain was assessed (using a visual analog scale [VAS] of 0–100) as quickly as possible after arrival in the PACU, and if the reported pain intensity was greater than 30, 3 mg of morphine was given. Assessment and treatment was repeated every 5 min until the reported VAS was 30 or less. Drug administration was stopped before the achievement of adequate pain relief only for respiratory depression (respiratory rate 12 bpm) or other serious events (e.g., hypotension, vomiting). Note that sedation was not considered a serious side effect. These investigators then examined the relationship between the initial pain score and amount of morphine required to achieve comfort. They reached several conclusions: 1. Patients with higher initial VAS pain scores required more incremental doses of morphine to reach an acceptable pain score (VAS 30). 2. There was a marked variation in the number of morphine doses required to produce comfort. The median dose to achieve a VAS of 30 or less was 0.17 mg/kg. 3. In general, VAS scores of 70 or more should be regarded as indicative of severe pain. 4. Most patients with a VAS score of 50 will usually require only one additional dose of morphine to report a VAS of 30 or less.

Hypoxia and heat inhibit inducible nitric oxide synthase gene expression by different mechanisms in rat hepatocytes

Tropane alkaloids from the leaves and stem bark of Erythroxylon alaternifolium and Erythroxylon rotundifolium.

Identification of a Novel Metabolic Target for Bioactive Triterpenoids Biosynthesis in <i>Ganoderma</i> lucidum

Characterization of a novel levopimaradiene synthase gene responsible for the biosynthesis of terpene trilactones in Ginkgo biloba

Genome-wide transcriptome analysis reveals the regulatory network governing terpene trilactones biosynthesis in Ginkgo biloba

The transcription factor MYC2 positively regulates terpene trilactone biosynthesis through activating GbGGPPS expression in Ginkgo biloba

A 0.7e−rms-temporal-readout-noise CMOS image sensor for low-light-level imaging

Molecular cloning, characterization, and functional analysis of a gene encoding 3-hydroxy-3-methylglutaryl-coenzyme A synthase from Matricaria chamomilla

Comparative Transcriptomic Analysis Reveals the Regulatory Mechanism of Terpene Trilactones Improvement by Exogenous Methyl Jasmonate in Ginkgo biloba

Inferring the Regulatory Network of miRNAs on Terpene Trilactone Biosynthesis Affected by Environmental Conditions

Molecular Cloning and Characterization of 1-Hydroxy-2-methyl-2-(e)-butenyl-4-diphosphate Reductase Gene from Ginkgo Biloba

The Ginkgo biloba microRNA160–ERF4 module participates in terpene trilactone biosynthesis

Characterization and Transcriptional Profiling of Ginkgo biloba Mevalonate Diphosphate Decarboxylase Gene (GbMVD) Promoter Towards Light and Exogenous Hormone Treatments

Molecular Cloning, Characterization and Expression of A Manganese Superoxide Dismutase Gene from Ginkgo Biloba

Cloning and Functional Characterization of Two Germacrene A Oxidases Isolated from Xanthium sibiricum

Opioids: more to learn, improvements to be made.

Cloning and functional analysis of Gb4CL1 and Gb4CL2 from Ginkgo biloba

Mexican Children under 2 Years of Age Consume Food Groups High in Energy and Low in Micronutrients.

Combining Metabolic Profiling and Gene Expression Analysis to Reveal the Biosynthesis Site and Transport of Ginkgolides in Ginkgo Biloba L.

Characterisation of Two Genes Encoding Cytochrome P450 Mono-Oxygenases Involved in Gibberellin Biosynthesis in Apple (Malus×domesticaborkh.)

Effects of Different Stress Treatments on the Total Terpene Trilactone Content and Expression Levels of Key Genes in Ginkgo biloba Leaves